Using cannabidiol to help treat opioid use disorder
Cannabidiol in the treatment of opioid use disorder
This study is looking at whether a special gelcap with cannabidiol (CBD) can help people struggling with opioid use disorder by reducing cravings and anxiety, and it’s designed for anyone who wants to explore new treatment options for their recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11173928 on NIH RePORTER |
What this research studies
This research investigates the potential of cannabidiol (CBD), a non-intoxicating compound from cannabis, as a treatment for opioid use disorder (OUD). The study aims to improve the delivery and effectiveness of CBD through a novel gelcap technology that enhances its absorption in the body. Participants will be involved in a randomized, double-blind, placebo-controlled trial to assess how well this new formulation works in reducing cravings and anxiety related to opioid use. The research builds on previous findings that CBD can decrease drug-seeking behavior and cravings in individuals recovering from opioid addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking treatment options.
Not a fit: Patients who are not experiencing opioid use disorder or those who are currently using other forms of opioid treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective non-opioid treatment option for individuals struggling with opioid use disorder.
How similar studies have performed: Previous studies have shown promising results for the use of CBD in reducing cravings and anxiety in opioid users, indicating a potential for success in this novel approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hurd, Yasmin L. — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hurd, Yasmin L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.